20
Nov
2025
Merck Buys Cidara, Abbott Acquires Exact, & Function Flies
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
20
Nov
2025
Building a Rare Disease Company: Neil Kumar on The Long Run
Neil Kumar is today’s guest on The Long Run. Neil is the founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma. BridgeBio got started a little more than 10 years ago with an idea of creating what it calls a “hub and spoke” business model for rare disease drug development. The hope was to find opportunities that were biologically compelling,... Read More